Amikacin Dosing for a 2-Month-Old Infant (3.5 kg)
For a 2-month-old infant weighing 3.5 kg, administer amikacin 15 mg/kg/day divided into doses every 8-24 hours, which translates to approximately 52.5 mg/day. The specific dosing interval should be determined based on renal function and therapeutic drug monitoring.
Recommended Dosing Approach
Based on FDA labeling and clinical guidelines, there are two acceptable regimens for this infant 1:
Option 1: Standard Divided Dosing
- 15 mg/kg/day divided every 8 hours = 17.5 mg every 8 hours
- This provides consistent coverage and is the traditional approach
Option 2: Extended-Interval Dosing
- 15 mg/kg once daily = 52.5 mg once daily
- This approach is increasingly supported by evidence showing comparable efficacy with potentially reduced toxicity 2
The pediatric guideline specifically lists amikacin dosing as 15-22.5 mg/kg/day given every 8-24 hours 3, providing flexibility in the dosing interval based on clinical circumstances.
Key Considerations for This Age Group
Age-Specific Factors
At 2 months of age, this infant falls into a transitional category:
- Not a newborn (FDA defines newborns as requiring a 10 mg/kg loading dose followed by 7.5 mg/kg every 12 hours) 1
- Older infant/child dosing applies: 15 mg/kg/day divided appropriately 3, 1
Renal Function Considerations
- Infants at 2 months have more mature renal function than neonates but still require careful monitoring
- Research demonstrates that preterm and younger infants have significantly altered pharmacokinetics with higher risk of toxic trough levels 4
- This 3.5 kg infant at 2 months likely has adequate renal maturation for standard dosing, but therapeutic drug monitoring is essential
Therapeutic Drug Monitoring Requirements
Mandatory monitoring parameters 1:
- Peak concentrations (30-90 minutes post-infusion): Should be adequate for efficacy but avoid >35 mcg/mL
- Trough concentrations (just before next dose): Must remain <10 mcg/mL to minimize nephrotoxicity
- Serum creatinine: Baseline and during therapy
- Renal function assessment: Ongoing throughout treatment
Research confirms that once-daily dosing achieves higher peaks and lower troughs compared to divided dosing, with comparable efficacy and no increased nephrotoxicity 2.
Administration Details
Intravenous Administration 1
- Dilute in appropriate volume of normal saline or 5% dextrose
- Infuse over 1-2 hours in infants (longer than the 30-60 minutes used in adults)
- Use sufficient fluid volume to allow proper infusion time
Duration of Therapy
- Typical duration: 7-10 days 1
- Total daily dose should not exceed 15 mg/kg/day for routine infections 1
- If treatment beyond 10 days is needed, re-evaluate necessity and intensify monitoring of drug levels and renal/auditory function 1
Critical Safety Warnings
Nephrotoxicity Risk Factors
- Prolonged therapy (>10 days)
- Elevated trough concentrations (>10 mcg/mL)
- Concomitant nephrotoxic drugs
- Pre-existing renal impairment
Ototoxicity Monitoring
- Aminoglycosides carry risk of irreversible ototoxicity
- Particularly concerning in infants who cannot report hearing changes
- Consider baseline and follow-up auditory assessment if prolonged therapy is required
Common Pitfalls to Avoid
Do not use "newborn" dosing (10 mg/kg loading, then 7.5 mg/kg q12h) for a 2-month-old—this is only for neonates 1
Do not skip therapeutic drug monitoring—the narrow therapeutic index and serious toxicity risks make monitoring non-negotiable when therapy extends beyond 48 hours 1
Do not use total body weight for obese patients—though less relevant in infants, dosing should be based on appropriate weight 1
Do not continue beyond 10 days without reassessment—prolonged therapy significantly increases toxicity risk 1
Clinical Context
For complicated intra-abdominal infections (the context of the guideline evidence), amikacin is typically combined with other agents for broader coverage. The aminoglycoside component specifically targets aerobic Gram-negative bacteria 3. The guideline recommends aminoglycoside-based regimens as acceptable broad-spectrum therapy for pediatric complicated intra-abdominal infections 3.